中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
8期
1430-1433
,共4页
医院获得性肺炎%药敏%帕珠沙星%环丙沙星
醫院穫得性肺炎%藥敏%帕珠沙星%環丙沙星
의원획득성폐염%약민%파주사성%배병사성
Hospital-acquired pneumonia%Drug sensitivity%Pazufloxacin%Ciprofloxaci
目的：评价帕珠沙星与环丙沙星对医院获得性肺炎(HAP)的临床价值。方法：采用前瞻性、临床随机对照的方法,试验组用帕珠沙星注射液300mg,iv gtt,bid；对照组用环丙沙星200mg,iv gtt,bid,疗程7~10d,评价其临床疗效及安全性。结果：帕珠沙星组痊愈率(77.59%vs 53.45%),总有效率(89.66%vs 74.14%),细菌学总清除率(93.02%vs 80.1%),铜绿假单胞菌清除率(98.15%vs 75.0%)以及肺炎克雷伯菌清除率(97.78%vs 85.7%)均优于环丙沙星组,并具有统计学意义(P<0.05或P<0.01),另外帕珠沙星组不良事件发生率要小于环丙沙星组(15.52%vs 27.59%),具有统计学意义(P<0.05)。其他症状大多轻微,可自行缓解,不影响临床研究。结论：帕珠沙星治疗医院获得性肺炎疗效确切并优于环丙沙星,尤其对铜绿假单胞杆菌、肺炎克雷伯菌引起的感染疗效更优,且不良反应较少,即帕珠沙星是较环丙沙星与HAP流行病原菌吻合度更高的氟喹诺酮类抗生素。
目的：評價帕珠沙星與環丙沙星對醫院穫得性肺炎(HAP)的臨床價值。方法：採用前瞻性、臨床隨機對照的方法,試驗組用帕珠沙星註射液300mg,iv gtt,bid；對照組用環丙沙星200mg,iv gtt,bid,療程7~10d,評價其臨床療效及安全性。結果：帕珠沙星組痊愈率(77.59%vs 53.45%),總有效率(89.66%vs 74.14%),細菌學總清除率(93.02%vs 80.1%),銅綠假單胞菌清除率(98.15%vs 75.0%)以及肺炎剋雷伯菌清除率(97.78%vs 85.7%)均優于環丙沙星組,併具有統計學意義(P<0.05或P<0.01),另外帕珠沙星組不良事件髮生率要小于環丙沙星組(15.52%vs 27.59%),具有統計學意義(P<0.05)。其他癥狀大多輕微,可自行緩解,不影響臨床研究。結論：帕珠沙星治療醫院穫得性肺炎療效確切併優于環丙沙星,尤其對銅綠假單胞桿菌、肺炎剋雷伯菌引起的感染療效更優,且不良反應較少,即帕珠沙星是較環丙沙星與HAP流行病原菌吻閤度更高的氟喹諾酮類抗生素。
목적：평개파주사성여배병사성대의원획득성폐염(HAP)적림상개치。방법：채용전첨성、림상수궤대조적방법,시험조용파주사성주사액300mg,iv gtt,bid；대조조용배병사성200mg,iv gtt,bid,료정7~10d,평개기림상료효급안전성。결과：파주사성조전유솔(77.59%vs 53.45%),총유효솔(89.66%vs 74.14%),세균학총청제솔(93.02%vs 80.1%),동록가단포균청제솔(98.15%vs 75.0%)이급폐염극뢰백균청제솔(97.78%vs 85.7%)균우우배병사성조,병구유통계학의의(P<0.05혹P<0.01),령외파주사성조불량사건발생솔요소우배병사성조(15.52%vs 27.59%),구유통계학의의(P<0.05)。기타증상대다경미,가자행완해,불영향림상연구。결론：파주사성치료의원획득성폐염료효학절병우우배병사성,우기대동록가단포간균、폐염극뢰백균인기적감염료효경우,차불량반응교소,즉파주사성시교배병사성여HAP류행병원균문합도경고적불규낙동류항생소。
Objective:To evaluate the clinical value of pazufloxacin and lciprofloxacin in the treatment of hospital-acquired pneumonia Methods:A prospective parallel randomized controlled clinical study was conducted to compare the efficacy and safety with that of pazufloxacin and ciprofloxacin were administered intravenously at a dosage of 300mg and 200mg respectively twice daily for 7~10 days Results:The cure rates(77.59%vs 53.45%),overall clinical efficacious rates (89.66%vs 74.14%),total bacterial removal rates (93.02%vS 80.1%) pseudomonas aeruginosa removal rates(98.15%vs 75.0%)and Klebsiella pneumoniae removal rates (97.78%vs 85.7%)of the pazufloxacin group were superior to the ciprofloxacin group(P<0.05 or P<0.01) The incidence of adverse drug reactions of pazufloxacin group were less than ciprofloxacin group (15.52% vs 27.59%) with a statistics difference(P<0.05).No serious adverse event was reported in either group Conclusion:The pazufloxacin is effective and safe for the treatment of HAP,and it was superior to that of ciprofloxacin,especially to pseudomonas aeruginosa and Klebsiella pneumoniae removal The rates of adverse effect were small in pazufloxacin groups.Therefor,pazufloxacin was more relevant to popular pathogen of HAP than ciprofloxacin.
